Evidence map›Paper›PMID 29088828›Full record

ArticleOncotarget2017

Molecular profiling identifies prognostic markers of stage IA lung adenocarcinoma.

Jie Zhang, Jinchen Shao, Lei Zhu, Ruiying Zhao, Jie Xing, Jun Wang, Xiaohui Guo, Shichun Tu, Baohui Han, Keke Yu

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Jie ZhangShanghai Chest Hospital, Shanghai JiaoTong University, Department of Pathology, Shanghai, China.
Jinchen ShaoShanghai Chest Hospital, Shanghai JiaoTong University, Department of Pathology, Shanghai, China.
Lei ZhuShanghai Chest Hospital, Shanghai JiaoTong University, Department of Pathology, Shanghai, China.
Ruiying ZhaoShanghai Chest Hospital, Shanghai JiaoTong University, Department of Pathology, Shanghai, China.
Jie XingShanghai Chest Hospital, Shanghai JiaoTong University, Department of Pathology, Shanghai, China.
Jun WangTumor Initiation & Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla.
Xiaohui GuoBioinformatics Core, Sanford Burnham Prebys Medical Discovery Institute, La Jolla.
Shichun TuAllele Biotechnology & Pharmaceuticals, Inc., Nancy Ridge Drive, San Diego, USA.
Baohui HanShanghai Chest Hospital, Shanghai JiaoTong University, Department of Pulmonary Medicine, Shanghai, China.
Keke YuShanghai Chest Hospital, Shanghai JiaoTong University, Department of Pathology, Shanghai, China.
Shanghai Chest Hospital · CNShanghai Jiao Tong University · CNAllele Biotechnology (United States) · USDiscovery Institute · USSanford Burnham Prebys Medical Discovery Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously showed that different pathologic subtypes were associated with different prognostic values in patients with stage IA lung adenocarcinoma (AC). We hypothesize that differential gene expression profiles of different subtypes may be valuable factors for prognosis in stage IA lung adenocarcinoma. We performed microarray gene expression profiling on tumor tissues micro-dissected from patients with acinar and solid predominant subtypes of stage IA lung adenocarcinoma. These patients had undergone a lobectomy and mediastinal lymph node dissection at the Shanghai Chest Hospital, Shanghai, China in 2012. No patient had preoperative treatment. We performed the Gene Set Enrichment Analysis (GSEA) analysis to look for gene expression signatures associated with tumor subtypes. The histologic subtypes of all patients were classified according to the 2015 WHO lung Adenocarcinoma classification. We found that patients with the solid predominant subtype are enriched for genes involved in RNA polymerase activity as well as inactivation of the p53 pathway. Further, we identified a list of genes that may serve as prognostic markers for stage IA lung adenocarcinoma. Validation in the TCGA database shows that these genes are correlated with survival, suggesting that they are novel prognostic factors for stage IA lung adenocarcinoma. In conclusion, we have uncovered novel prognostic factors for stage IA lung adenocarcinoma using gene expression profiling in combination with histopathology subtyping.

Indexed as

acinardifferently expressed genes (DEGs)gene expression profilinglung adenocarcinomasolid

Identifiers

PMID29088828
PMCPMC5650383
OpenAlexW2749338396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.